Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion type Assertion NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_head.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion description "[Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and double-hit lymphoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_provenance.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion evidence source_evidence_literature NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_provenance.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion SIO_000772 25239935 NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_provenance.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion wasDerivedFrom befree-2016 NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_provenance.
- NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_assertion wasGeneratedBy ECO_0000203 NP1222134.RAkhz5O9XVZJdVn1UafKfBqAfvkb6-7VdeJw_FvEALeBo130_provenance.